Recent advances in lab-on-a-chip technology establish solid foundations for wearable biosensors. These newly emerging wearable biosensors are capable of non-invasive, continuous monitoring by miniaturization of electronics and integration with microfluidics. The advent of flexible electronics, biochemical sensors, soft microfluidics, and pain-free microneedles have created new generations of wearable biosensors that explore brand-new avenues to interface with the human epidermis for monitoring physiological status. However, these devices are relatively underexplored for sports monitoring and analytics, which may be largely facilitated by the recent emergence of wearable biosensors characterized by real-time, non-invasive, and non-irritating sensing capacities.
Miniaturization of laboratory apparatus into microscale devices is a promising technology called lab-on-a-chip (LOC) [1]. About 30 years ago the concept of micro total analysis systems (μTAS) emerged from the field of semiconductor fabrication and was enhanced by microelectromechanical systems (MEMS) technologies [2,3,4]. The μTAS concept is to shrink an entire analytical procedure, such as cell sorting, single-cell capture, captured-cell transport, cell lysis, and intracellular analysis, into a miniaturized multifunctional chip [5,6,7], and nowadays its well-known synonym is called lab-on-a-chip (LOC) [3,4]. This growing field has garnered considerable attention since scaled-down biochemical analysis has several key advantages over both conventional and current laboratory benchtop methods [3,5]. These advantages are consistently demonstrated in clinical medicine, engineering, biology, and life science, etc., for example, to expedite the experimental process by embracing automation and parallelization [1,8,9]; to lower the cost by reducing the volume of expensive reagents [1,5,10,11]; to yield better interpretation of experimental results by gleaning vital information at cellular even molecular levels [12,13,14].
Interest in device miniaturization [15,16,17], combined with advances in bio-microfabrication and enabling materials [18], is motivating various microfluidic methods in which microchips can be mass-manufactured at extremely low cost via polymers (e.g., polydimethylsiloxane, PDMS) and soft lithography for microfabrication [5,19]. Microfluidics is the science of microscale devices that process and manipulate extremely low (10−9 to 10−18 L) amounts of fluids in microchannels with dimensions of tens of micrometers [10]. Conventional macroscale experimental technologies meet difficulties to deal with such low amounts of fluids, impeding their development in various fields. Conversely, microfluidic technologies begin to address numerous tough challenges, because fluid phenomena at the microscale are dramatically different from those at the macroscale [3]. For instance, capillary forces and surface tension are more dominant than gravitational forces [3], allowing for passively pumping fluids in opposition to gravity [20]. Flows at the microscale are laminar instead of turbulent, resulting in more predictable liquid handling and diffusion kinetics [5]. Based on the different phenomena behaving at the microscale, microfluidic technologies offer a sensitive, predictable, and controllable avenue for bioanalysis [21].
Despite all the attractive capacities of LOC/microfluidics devices that have enabled the widespread implementation of microchip-based systems in biology and life science [3,4,5,22], microfluidic technologies often only improve the performance of existing macroscale assays or provide equivalent alternatives [13]. Conversely, they have not reached their full potential due to the lack of essentially new capacities [3]. In recent years, however, LOC/microfluidics technologies begin to address some problems that have not yet been solved by current laboratory benchtop methods. An excellent example can be found in wearable/ambulatory healthcare monitoring and sports analytics harnessing skin-interfaced wearable biosensors [15,23]. Although this field is still in its infancy, the fundamentals of it are exceptionally strong: in the past decade, the wearable LOC devices gradually integrated with well-established techniques, including biocompatible materials [24,25], flexible electronics [26,27,28,29,30], optical/electrochemical sensors [14,26,31,32], microfluidics [21,33,34,35], near-field communications (NFC) [36], pain-free microneedles [37,38,39,40], as well as big data and cloud computing [14,41,42].
These above-mentioned enabling techniques establish the foundations for a new generation of wearable biosensors that directly interfaced with the human epidermis instead of rigid packages embedded in wrist straps or bands [23,43,44,45]. The distinguishing characteristics of the emerging wearable biosensors, lightweight, flexibility, and portability [31,36,46], have made them especially suitable for point-of-care testing (POCT). Therefore, brand-new wearable biosensors capable of real-time physiological monitoring quickly emerge, as shown in Figure 1. However, these wearable biosensors are mainly designed for health monitoring [15,34,41,45,47,48], especially, some of them are only developed to measure the physical strain/stress bending change [25,49,50]. Although many wearable devices have been deployed in sports, they are used to monitoring biophysical markers [23], such as movement [51] and cardiovascular information (e.g., blood oxygenation) [26,52,53].
Several decades ago, microneedles (MNs) were first introduced to perform transdermal drug delivery [179]. MNs with small length (usually less than 1000 μm [180,181]) penetrate the stratum corneum and open windows for the ISF biosensing or form transient microchannels for drug delivery while preventing the nerves and blood vessels from stimulation and impairment. Currently, MNs have been utilized for applications in the following areas: ISF sampling [180,182], disease diagnostics [153,183,184], drug delivery [179,185,186], cosmetics [181,187,188,189], etc.
MNs have wide applications and show tremendous promise for applying biomedical advances into wearable healthcare and sports monitoring due to the three following intrinsic advantages.
Enhanced compliance. The patients and athletes will not suffer from pain, discomfort, and needle-phobia [179,180,190,191].
Easy-to-use. MNs are user-friendly biosensing and drug delivery devices that can be directly applied to the skin. Conventional methods, hypodermic injections, conversely, demand professional personnel who undergo rigorous medical training [179].
Real-time in situ biosensing and controllable/long-term drug delivery. MNs realize pain-free, in situ diagnostics even combine with feedback-based long-term drug delivery [160].
Recent advances in wearable MN patches capable of minimally-invasive, transdermal sensing biofluids [153,160,179,192,193] and pain-free drug delivery [184,194,195] provide an opportunity to perform sports monitoring, especially beneficial to sports nutrition and sports medicine [196]. These techniques combined with electrochemical/microfluidic biosensing modalities are expected to lead to several breakthroughs in wearable biosensing.
Microneedles for transdermal drug delivery reduce the systemic side effects and improve dosage efficacy and patient compliance [180] compared to hypodermic needles [38,180,202]. Typically, external small molecules (e.g., drug contents) can be minimally-invasive delivered percutaneously harnessing passive mass transfer. To facilitate the establishment of closed-loop diagnostic and therapeutic systems, MNs for drug delivery are also attractive, especially for controlled or long-term non-irritating drug release. In the past few years, great efforts have been made to find a way for controllable/long-term drug delivery using MNs, such as thermo-responsive MNs [153], stretch-triggered MNs [196], multilayered MNs [38], and effervescent MNs [40].
To deliver the drug contents in a controllable manner, Lau et al. [38] developed a multilayered pyramidal dissolving MN patch with flexible pedestals (Figure 11c). The drug release time and rate were regulated by the dissolution rate of diverse biomaterials in different layers of the MNs. Hence, the MNs were applicable to control the release rate of the anti-inflammatory drug to facilitate personalized sports medicine. For instance, the rapid dissolution of the tip’s outermost layer of the multilayered pyramidal MNs can quickly control inflammation and continuously treat chronic inflammation via sustained dissolution of the inner layer.
Another group demonstrated the pursuit of long-term personalized drug delivery. Wei Li et al. [40] developed an effervescent system to increase access to long-acting contraception (Figure 11d). The MNs consisted of drug-loaded tips and effervescent backings containing polyvinylpyrrolidone (PVP), sodium bicarbonate, and citric acid. Once inserted in the skin, the ISF solubilized the effervescent backing and the CO2 generated from the reaction of citric acid with sodium bicarbonate facilitated the separation of the interfaces between the MNs’ tips and patch backings (detachment efficiency of 91.7 ± 2.4%). Long-acting contraception was achieved in vivo by the dissolution of MNs’ tips to release levonorgestrel (LNG) for 2 months and maintained the LNG concentrations above the human contraceptive threshold level for >1 month (after rats being administered MNs).
In sum, MNs are not only appealing avenues to interrogate the ISF for biosensing, to carry out controllable/long-term transdermal drug delivery [179,185,186], but also can facilely incorporate with electrochemical biosensors [157,169,181] to realize closed-loop personalized diagnostics and therapeutics [153,193,203]. Moreover, recent advances in biofuel cells [89,200,204,205,206] could further address the key issue, lack of thin and reliable wearable power sources. These eminent features would enable a broad range of important applications in the sports field where real-time athletic performance monitoring and personalized sports injury treatments are urgently demanded [196]. We envisage that the advancement of MNs for biosensing and drug delivery will encourage the emergence of new generations of wearable athletic biosensors, that would revolutionize sports monitoring and sports medicine in the near future.
Recent advances in stretchable materials, microfluidics, optical/electrochemical sensors, image processing and analysis, NFC and wireless power supply, microneedles, as well as big data and cloud computing provide a robust foundation for wearable biosensing, especially the field of microfluidics for sweat and ISF biosensing. The emerging sampling and sensing modalities for obtaining sweat biochemical information offer profound insights into human physiology, metabolism, and sports performance, which complement traditional biophysical sensing modalities. Representative examples of wearable biosensors capable of in situ monitoring sweat biomarkers, from electrolytes, metabolites, heavy metals, cytokines [146], hormones [80,148,149], amino acids [150] to exogenous drugs [83,156], provide a window on the valuable biochemical resources that have a substantial impact on disease diagnostics, precision medicine, drug delivery, and sports analytics. However, the majority of advanced wearable sweat biosensors still focus on healthcare monitoring to improve home-based disease diagnosis. Although wearable biosensors for sports analytics are underdeveloped, the transition from focusing on healthcare monitoring to combining with sports analytics is an important step in a trend towards better preventive healthcare and sports & health science. It offers revolutionary capacities for future wearable technologies. It also in its infancy, and a great deal of work still needs to be done, such as integration of well-developed technologies (e.g., ultrasonics, implants, optofluidics, optoelectronics, microneedles, etc.), for building up a picture of future biosensing technologies. Despite the remarkable progress that several research groups achieved over the past five years, daunting challenges remain in the power supply, data interpretation, the cost of mass-fabrication, as well as in-depth interdisciplinary collaboration. With these challenges overcome, the commercialization and widespread adoption of wearable biosensors in sport-related fields will be fully realized, and state-of-the-art athletic monitoring and sports analytics will be transformed fundamentally.
This entry is adapted from the peer-reviewed paper 10.3390/bios10120205